ArticleJournal of molecular histology2025
Mitigating cardiotoxicity and nephrotoxicity: the role of naringin-dextrin nanoparticles in male Wistar rats.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of mitochondrial dysfunction, oxidative stress, and gender in cardiac fibrosis and vascular remodeling in an induced aged rat model with possible mitigation by eugenol nano-emulsion.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Nanoparticles are the fundamental building blocks of nanotechnology with numerous scientific applications. New advancements in nanotechnology have revealed uses for nanoparticles in various medicinal applications. This study investigated the chemoprotective effects of naringin-dextrin nanoparticles (NNPs) against diethylnitrosamine (DEN)-induced cardio-nephrotoxicity in Wistar rats. Cardio-nephrotoxicity was induced in Wistar rats via intraperitoneal DEN injection (150 mg/kg body weight (b.w.) per week) for 2 weeks, followed by oral administration of 2-acetylaminofluorene (2AAF) (20 mg/kg b.w.) four times per week for 3 weeks. Rats were then treated every other day for 24 weeks with either 10 mg/kg body weight of naringin (Nar) or 10 mg/kg body weight of NNPs. Nar and NNP treatments reduced biochemical markers of heart and kidney and improved tissue morphology compared to the DEN-treated group. These results were linked to a notable reduction in malondialdehyde (MDA) and nitric oxide (NO) levels, upregulation of antioxidant enzyme superoxide dismutase (SOD) activity, and enhanced glutathione (GSH) and nuclear factor erythroid 2-related factor 2 protein (NRF2) expression in the heart and kidneys. Nar and NNPs exerted an anti-inflammatory effect, manifested by a decrease in heart and kidney protein expression of tumor necrosis factor-α (TNF-α) and inducible nitric oxide synthase (iNOS), with a concurrent increase in interleukin-4 (IL-4) expression, though this effect was more potent with NNPs than Nar. Regarding the effect on apoptosis, both Nar and NNPs significantly reduced the protein expression of p53 and caspase-3. Nar and NNPs effectively improved oxidative stress, inflammation, and tissue damage associated with DEN/AAF-induced cardio-nephrotoxicity.
Indexed as
Identifiers
41219625What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.